VALEANT PHARMACEUTICALS INTERNATIONAL (NY:VRX)
35.55
-0 (-0%)
| VALEANT PHARMACEUTICALS INTERNATIONAL (NY:VRX) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $35.55 | 52 Week High | $35.80 | ||
| Open | $34.76 | 52 Week Low | $15.64 | ||
| Day High | $35.69 | P/E | N/A | ||
| Day Low | $34.56 | EPS | $-0.45 | ||
| Volume | 811,879 | ||||
| More VRX Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| GSK | 5 | CHIC | 2 |
| FNM | 2 | AZN | 2 |
| FRE | 2 | EYE | 2 |
| TFX | 2 | NRP | 2 |
| PG | 2 | WCRX | 2 |
| X | 1 | NVS | 1 |
Entities who have mentioned VRX
- Matrix USA | View Related Stories »
- Citi | View Related Stories »
- Soleil Securities | View Related Stories »
- JPMorgan | View Related Stories »
- Jefferies & Co | View Related Stories »
- 13G | View Related Stories »
- Notable Analyst Rating Changes | View Related Stories »
- Morgan Stanley | View Related Stories »
- JANA Partners LLC | View Related Stories »
- Barry Rosenstein | View Related Stories »
- Wachovia | View Related Stories »
- Daniel Loeb | View Related Stories »
- Lehman Brothers | View Related Stories »
- Brean Murray Carret & Co. | View Related Stories »
- Notable Mergers and Acquisitions | View Related Stories »
- Credit Suisse | View Related Stories »
- Unusual 11 Mid-Day Movers | View Related Stories »
- Goldman Sachs | View Related Stories »
- 13D | View Related Stories »
- Life, Style and Real Estate | View Related Stories »
- Susquehanna International Group of Companies | View Related Stories »
- Bear Stearns | View Related Stories »
- UBS | View Related Stories »
- Greenlight Capital | View Related Stories »
- Merrill Lynch | View Related Stories »
View All Major News StreetInsider.com Major News for VRX
- Valeant Pharma (VRX) Posts non-GAAP EPS of $0.58; Raises FY09 EPS Guidance
- Valeant Pharmaceuticals (VRX) Tops Q2 EPS by 7c; Guides Above
- Valeant Pharmaceuticals (VRX) Tops Q1 View By 14c; Raises Prior Guidance
View All ReportsStreetInsider.com Reports on VRX
- Jefferies & Co Initiates Coverage on Valeant Pharmaceuticals (VRX) with a Buy
- Teleflex Inc. (TFX) Names Richard 'Randy' Meier to EVP and CFO
- Valeant Pharma (VRX) Says FDA Accepts NDA Filing for Retigabine
- Valeant Pharma (VRX) Subsidiary to Acquire Laboratoire Dr. Renaud in C$23M Transaction
- Valent Pharma (VRX) Shares Ride the Lightning, But Is the Storm Breaking? - Barron's (GSK)
View All Press ReleasesCompany Press Releases on VRX
- Valeant Pharmaceuticals to Announce 2009 Fourth Quarter and Year Results on February 22, 2010
- Four Worksites Awarded CEO Cancer Gold StandardTM Accreditation
- Teleflex Incorporated Names Richard (Randy) Meier Chief Financial Officer
- Valeant Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
- Valeant Pharmaceuticals to Hold Conference Call to Announce 2010 Financial Guidance
StreetInsider Reports on VRX by Category
View All BlogsBlogs on VRX
- Valeant Pharma (VRX) falls on bearish Barron's coverage
- 37 Breakout Stocks on Big Volume, November 16, 2009
- Valeant Pharmaceuticals International Q3 2009 Earnings Call Transcript
- Valeant: It Turns Out that Wrinkles Are Worth Quite a Lot
- Tupperware: Unlikely Market Leader
View All FilingsSEC Filings on VRX
- Form 4 VALEANT PHARMACEUTICALS For: Feb 01 Filed by: Pearson J. Michael
- Form SC 13G/A VALEANT PHARMACEUTICALS Filed by: IRIDIAN ASSET MANAGEMENT LLC/CT
- Form SC 13G/A VALEANT PHARMACEUTICALS Filed by: FRANKLIN MUTUAL ADVISERS LLC
- Form 4 VALEANT PHARMACEUTICALS For: Jan 21 Filed by: DE SILVA RAJIV
- Form 8-K VALEANT PHARMACEUTICALS For: Jan 05
Comments on VRX
No comments are currently available.
